Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Webcasts|October 8, 2020
Does Your Clinical Trial Design Satisfy the Needs of Your Patients?
*** Live: Thursday, November 5, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET***At the center of every clinical trial is a patient awaiting treatment. Learn from the experts on how to design a decentralized clinical trial to improve patient recruitment and retention. ***On demand available after final airing until Nov. 5, 2021***
Register free:
Event Overview:
Decentralized clinical trials were on the rise even before the Covid-19 pandemic. But how do you know if it makes sense for your trial? Simply put, a decentralized clinical trial eliminates the need for a patient to visit an investigator site to receive treatment. While this patient-centric design increases convenience and provides an uninterrupted flow of medication for the patient, it can also positively impact trial enrollment and retention for Sponsors.
Key Learning Objectives:
- How to determine if a decentralized clinical trial is the right choice
- How to build a patient-centric supply chain
- The benefits of working with a single source provider
Speaker: Rodman Stull, Vice President & General Manager, Clinical Services, North America, Thermo Fisher Scientific
Jason Mieding, Global Leader, Total Transportation Management, Thermo Fisher Scientific
Time and Date: Thursday, November 5, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET
On demand available after final airing until Nov. 5, 2021
Register free:
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5